Actas Urol Esp (Engl Ed)
- MUNIZ SUAREZ L, Subira Rios J, Gayarre Abril P, Montero Martoran A, et al
Influence of laparoscopic surgery on the outcomes of radical cystectomy within a
multimodal rehabilitation protocol.
Actas Urol Esp (Engl Ed). 2024;48:364-370.
Anal Chem
- WU N, Wong KY, Yu X, Zhao JW, et al
Multispectral 3D DNA Machine Combined with Multimodal Machine Learning for
Noninvasive Precise Diagnosis of Bladder Cancer.
Anal Chem. 2024 Jun 6. doi: 10.1021/acs.analchem.4c01749.
Ann Oncol
- POWLES T, Bellmunt J, Comperat E, De Santis M, et al
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced
urothelial carcinoma.
Ann Oncol. 2024;35:485-490.
Arch Esp Urol
- TIAN F, Wei Y, Wang T, Yuan X, et al
Letter to the Editor Re: Treatment Progress of Compound Kushen Injection and
Gemcitabine in Postoperative Patients with Bladder Cancer and Selection of Drug
Delivery Mode.
Arch Esp Urol. 2024;77:453-454.
Asia Pac J Oncol Nurs
- KIM SH, Ryu E, Jeong BC
Role performance and factors affecting quality of life in bladder cancer
survivors with ileal orthotopic neobladder.
Asia Pac J Oncol Nurs. 2024;11:100490.
Asian J Surg
- YE L, Lu L, Feng D, Ke M, et al
DMRT1 could serve as a prognostic biomarker for bladder cancer patients.
Asian J Surg. 2024 Jun 3:S1015-9584(24)01111.
Biomed Pharmacother
- WU L, Hu Z, Song XF, Liao YJ, et al
Targeting Nrf2 signaling pathways in the role of bladder cancer: From signal
network to targeted therapy.
Biomed Pharmacother. 2024;176:116829.
BMJ Case Rep
- VARRIOR AR, Thakkar H, Kale S
Radiological features of multifocal embryonal rhabdomyosarcoma affecting the
vagina and the urinary bladder in a pediatric patient.
BMJ Case Rep. 2024;17:e259549.
Cancer Lett
- SHEN C, Liu J, Xie F, Yu Y, et al
N6-Methyladenosine enhances the translation of ENO1 to promote the progression of
bladder cancer by inhibiting PCNA ubiquitination.
Cancer Lett. 2024;595:217002.
Cancer Manag Res
- ZHANG X, Ma L
Predictive Value of the Total Bilirubin and CA50 Screened Based on Machine
Learning for Recurrence of Bladder Cancer Patients.
Cancer Manag Res. 2024;16:537-546.
Cancer Prev Res (Phila)
- JIN F, Thaiparambil J, Donepudi SR, Vantaku V, et al
Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts,
and DNA Damage in Bladder Cancer.
Cancer Prev Res (Phila). 2024;17:281.
Cell Cycle
- ZHOU W, Yang Y, Wang W, Yang C, et al
Pseudogene OCT4-pg5 upregulates OCT4B expression to promote bladder cancer
progression by competing with miR-145-5p.
Cell Cycle. 2024 Jun 6:1-17. doi: 10.1080/15384101.2024.2353554.
Clin Genitourin Cancer
- NARITA C, Urabe F, Fukuokaya W, Iwatani K, et al
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among
Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a
Multicenter Cohort Study.
Clin Genitourin Cancer. 2024;22:102082.
- VLACHOU E, Mamtani R, Hahn NM, Iii BJ, et al
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab
Vedotin.
Clin Genitourin Cancer. 2024;22:102090.
- CHEN J, Wang M, Qi X, Long H, et al
RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter
Real-World Study in China.
Clin Genitourin Cancer. 2024;22:102093.
- FLEMING S, Gifkins D, Resnick HE, Shalaby W, et al
Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in
Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:102054.
- TAPIA JC, Bosma F, Gavira J, Sanchez S, et al
Treatment Patterns and Survival Outcomes Before and After Access to Immune
Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A
Single-Center Retrospective Study From 2004 to 2021.
Clin Genitourin Cancer. 2024;22:102047.
Clin Lab Med
- AL-AHMADIE H, Netto GJ
Molecular Pathology of Urothelial Carcinoma.
Clin Lab Med. 2024;44:181-198.
Clin Med Insights Oncol
- BALLI S, Bolek H, Urun Y
Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder
Cancer and Renal Cell Carcinoma Treatments.
Clin Med Insights Oncol. 2024;18:11795549241257238.
Curr Oncol Rep
- LINSCOTT JA, Miyagi H, Murthy PB, Yao S, et al
From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder
Cancer.
Curr Oncol Rep. 2024 Jun 5. doi: 10.1007/s11912-024-01555.
Curr Opin Urol
- FAZEKAS T, Miszczyk M, Matsukawa A, Nyirady P, et al
Defining oligometastatic state in uro-oncological cancers.
Curr Opin Urol. 2024;34:261-265.
Eur J Nutr
- BOOT IWA, Wesselius A, Jochems SHJ, Yu EYW, et al
Fruits and vegetables intake and bladder cancer risk: a pooled analysis from 11
case-control studies in the BLadder cancer Epidemiology and Nutritional
Determinants (BLEND) consortium.
Eur J Nutr. 2024 Jun 5. doi: 10.1007/s00394-024-03436.
Fr J Urol
- BLACHIER M, Ye H, Long JA, Descotes JL, et al
Interest of the POSPOM score in estimating postoperative complication risk after
radical cystectomy.
Fr J Urol. 2024;34:102610.
Front Oncol
- GALBIATI S, Bettiga A, Colciago G, Senti C, et al
The long noncoding RNA SUMO1P3 as urinary biomarker for monitoring bladder cancer
progression.
Front Oncol. 2024;14:1325157.
- ZHANG Y, Guo X, Zhang Y, Wei J, et al
A preliminary investigation of precise visualization, localization, and resection
of pelvic lymph nodes in bladder cancer by using indocyanine green
fluorescence-guided approach through intracutaneous dye injection into the lower
limbs and perineum.
Front Oncol. 2024;14:1384268.
Front Public Health
- BABADI F, Ahmadi A, Sarkarian M, Cheraghi M, et al
Relationship between oral health literacy and oral health-related quality of life
in patients with bladder cancer.
Front Public Health. 2024;12:1385443.
Heliyon
- HUANG Y, Chen L, Zou Y, Yu H, et al
Bibliometric insights into drug resistance in bladder cancer: Two decades of
progress (1999-2022).
Heliyon. 2024;10:e31587.
Int Immunopharmacol
- ZHANG J, Huang Y, Tan X, Wang Z, et al
Integrated analysis of multiple transcriptomic approaches and machine learning
integration algorithms reveals high endothelial venules as a prognostic
immune-related biomarker in bladder cancer.
Int Immunopharmacol. 2024;136:112184.
Int J Oncol
- THI TN, Thanh HD, Nguyen VT, Kwon SY, et al
Complement regulatory protein CD46 promotes bladder cancer metastasis through
activation of MMP9.
Int J Oncol. 2024;65:71.
Int J Surg
- WANG Z, Zhang G, Liu X, Tan G, et al
A commentary on "Single-cell and bulk RNA-sequence identified fibroblasts
signature and CD8+ T cell - Fibroblast subtype predicting prognosis and immune
therapeutic response of bladder cancer, based on machine-learning" (Int J Surg.
2024 May 17.).
Int J Surg. 2024 Jun 4. doi: 10.1097/JS9.0000000000001769.
Int J Urol
- NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
Does radical cystectomy have a better prognosis than bladder conservative
treatment in the real world?
Int J Urol. 2024;31:628-636.
- UEMURA K, Ito H, Jikuya R, Kondo T, et al
Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma
following pembrolizumab therapy in real-world data.
Int J Urol. 2024;31:678-684.
- MIKI J, Fukuokaya W, Taoka R, Saito R, et al
Oncological outcomes of prophylactic urethrectomy at the time of radical
cystectomy for bladder cancer: A nationwide multi-institutional study.
Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
- FU H, Hillman E, Talluri S, Liang L, et al
Comparison of the perioperative outcomes of using the Firefly system with
indocyanine green during robotic-assisted cystectomy with urinary diversion.
Int J Urol. 2024;31:646-652.
- HARA T, Matsushita Y, Harada K, Fujimoto N, et al
Clinical outcomes in patients with advanced urothelial carcinoma treated with
enfortumab vedotin: A retrospective multicenter study in Japan.
Int J Urol. 2024;31:696-698.
Int Urogynecol J
- CARBONE L, Webber V, Rothenberger R, Lenger SM, et al
Robotic Vaginal Hernia Repair for Recurrent Vaginal Prolapse Status Post-Radical
Cystectomy with an Indiana Pouch.
Int Urogynecol J. 2024;35:1097-1099.
J Cell Mol Med
- LI H, Ma H, Ma J, Qin F, et al
Unveiling the role of RAC3 in the growth and invasion of cisplatin-resistant
bladder cancer cells.
J Cell Mol Med. 2024;28:e18473.
J Exp Med
- TRAN MA, Youssef D, Shroff S, Chowhan D, et al
Urine scRNAseq reveals new insights into the bladder tumor immune
microenvironment.
J Exp Med. 2024;221:e20240045.
J Magn Reson Imaging
- KONG L, Li H, Cai Q, Cao W, et al
Amide Proton Transfer-Weighted Imaging in Assessing the Aggressive and
Proliferative Potential of Bladder Cancer.
J Magn Reson Imaging. 2024 Jun 1. doi: 10.1002/jmri.29464.
Minerva Urol Nephrol
- CICIONE A, Lombardo R, Nacchia A, Franco A, et al
No clinical benefit from sequential combination of mitomycin C plus bacillus
Calmette-Guerin (BCG) than BCG alone in the adjuvant treatment of high risk non
muscle invasive bladder cancer: result of a planned interim analysis of a
prospective randomiz
Minerva Urol Nephrol. 2024 Jun 5. doi: 10.23736/S2724-6051.24.05777.
Mol Biotechnol
- LI J, Feng S, Wang X, Zhang B, et al
Exploring the Targets and Molecular Mechanisms of Curcumin for the Treatment of
Bladder Cancer Based on Network Pharmacology, Molecular Docking and Molecular
Dynamics.
Mol Biotechnol. 2024 Jun 1. doi: 10.1007/s12033-024-01190.
Nat Commun
- JUAN RAMON A, Parmar C, Carrasco-Zevallos OM, Csiszer C, et al
Development and deployment of a histopathology-based deep learning algorithm for
patient prescreening in a clinical trial.
Nat Commun. 2024;15:4690.
Nat Med
- LI R, Shah PH, Stewart TF, Nam JK, et al
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive
non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03025.
Oncol Res
- KIM H, Cho U, Hong SH, Park HS, et al
New insights into ATR inhibition in muscle invasive bladder cancer: The role of
apolipoprotein B mRNA editing catalytic subunit 3B.
Oncol Res. 2024;32:1021-1030.
Pathol Res Pract
- YAN B, Luo P, Qiu H, Wang J, et al
PC4 promotes bladder cancer progression and stemness by directly interacting with
Sp1 to transcriptionally activate the Wnt5a/beta-catenin pathway.
Pathol Res Pract. 2024;259:155369.
Sci Rep
- ZHANG T, Zhu J, Li Z, Zhao Y, et al
The UF-5000 Atyp.C parameter is an independent risk factor for bladder cancer.
Sci Rep. 2024;14:12659.
Transl Oncol
- ZUCCA LER, Laus AC, Sorroche BP, Paro E, et al
Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder
cancer.
Transl Oncol. 2024;46:102003.
Urol Int
- OZCAN L, Polat EC, Baran C, Boylu A, et al
Systemic Inflammatory Index: A Promising Non-Invasive Marker for the Prediction
of Response to Neoadjuvant Chemotherapy prior to Cystectomy.
Urol Int. 2024;108:226-233.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016